Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

P. Conte, A. Frassoldati, G. Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Molino, A. Musolino, A. Ferro, R. Maltoni, S. Danese, C. Zamagni, A. Rimanti, K. Cagossi, A. RussoP. Pronzato, F. Giovanardi, G. Moretti, L. Lombardo, A. Schirone, A. Beano, L. Amaducci, E.A. Bajardi, R. Vicini, S. Balduzzi, R. D'Amico, V. Guarneri, Reader study level-I and level-II Groups

Research output: Contribution to journalArticle

Cite this

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., ... Groups, R. S. L-I. A. L-II. (2018). Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Annals of oncology : official journal of the European Society for Medical Oncology, 29(12), 2328-2333. https://doi.org/10.1093/annonc/mdy414